ASH 2022 | Understanding the risk of progression of smoldering myeloma to provide more personalized therapies
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, explains the importance of understanding the risk of progression of smoldering myeloma to multiple myeloma to determine the best treatment strategy for each patient. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sognef: Honoraria; Bristol Myers Squibb: Honoraria; GSK: Honoraria; Huron Consulting: Honoraria; Veeva Systems: Honoraria; Vor Biopharma: Honoraria; Aptitude Health: Honoraria; Sanofi: Honoraria; Menarini Silicon Biosystems: Honoraria; Window Therapeutics: Other: Advisory board participation; The Binding Site: Honoraria; Takeda: Honoraria; Pfizer: Honoraria; Oncopeptides: Honoraria; Janssen: Honoraria; Amgen: Honoraria; Adaptive: Honoraria; AbbVie: Honoraria; Novartis: Research Funding; Celgene: Research Funding.
